Table 3.
Frailty patterns self-reported by prostate cancer patients by androgen deprivation therapy (ADT) exposure. Data are expressed as % of sample.
| Characteristic | Current ADT (N=120) | Past ADT (N=62) | Never ADT (N=99) | p-value |
|---|---|---|---|---|
| Frailty Phenotype (%) | ||||
| Robust | 60.0% | 56.9% | 85.1% | |
| Pre-frail | 29.6% | 32.8% | 13.8% | <0.01* |
| Frail | 10.4% | 10.3% | 1.1% | |
| Obese Frailty Phenotypea (%) | ||||
| Robust | 37.9% | 41.4% | 74.7% | |
| Pre-frail | 47.4% | 43.1% | 24.2% | <0.01* |
| Frail | 14.7% | 15.5% | 1.1% | |
| Frailty Component (%) | ||||
| Resistance | 15.3% | 16.4% | 3.1% | <0.01 |
| Exhaustion | 19.5% | 24.2% | 8.2% | 0.02 |
| Ambulation | 27.6% | 25.4% | 3.2% | <0.01* |
| Illness | 3.3% | 4.8% | 0.0% | 0.12 |
| Weight loss | 10.9% | 8.2% | 5.1% | 0.30 |
| Obesitya | 40.8% | 40.3% | 16.2% | <0.01* |
*
p-value <0.001
a
Obese frailty phenotype calculated by substituting weight loss component of original frailty phenotype with obesity component = BMI ≥ 30 kg/m2.